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The cost of treatment is covered by health insurance and is 
continued in health centers, at home of patients and in the inclu-
sive school departments. Patients with neuromuscular diseases 
from other (mostly rural) areas are also allowed to rehabilitate 
in these institutions.
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Duchenne  and  Becker  muscular  dystrophies  have  similar 
signs and symptoms and are caused by different mutations in the 
same gene. The two conditions differ in their severity, age of on-
set, and rate of progression. The signs and symptoms of Becker 
muscular dystrophy are usually milder and exhibit a large range 
of variation. In most cases, muscle weakness becomes apparent 
later in childhood or adolescence and progresses at a much slower 
rate. Individuals can remain ambulatory into their 40s. Despite 
the milder skeletal muscle involvement, heart failure from dilated 
cardiomyopathy (DCM) is a common cause of morbidity and the 
most common cause of death, in the mid-40s. Two hot-spots BMD 
mutations have been described, at the 5’ end of the dystrophin 
gene, comprising exons 2 to 11 and at the 44-45 exon level.The 
most part of BMD patients present a deletion of the exons 45-48 
or 45-49. We present cardiological data – retrospectively evalu-
ated – from 16 Becker patients, aged from 7 to 52 years, sharing a 
deletion involving exon 48 alone. The mean age of the follow-up 
was 6,6 years (range 1-13,9). Cardiac function was evaluated, at 
6-month intervals, by standard and dynamic Ecg, Mono and 2D-
echocardiography, echocolor-doppler-cardiography. The following 
cardiologic parameters were considered: Heart Rate, PQ interval, 
PQ segment, QT interval, Cardiomyopathic Index, T wave anoma-
lies, presence of ectopic ventricular beats, ventricle diameters, left 
ventricular free wall and septum thickness, ejection fraction, fiber 
shortening, integrated back scattering. Data collected at the last 
control, compared with those at the time of the first control, show 
that no sign or symptom of cardiomyopathy is evident in these 
patients, suggesting that BMD patients sharing deletions limited to 
exon 48, seem to escape dystrophinopathic cardiomyopathy for a 
long time. The possible causes of such a condition are discussed.
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Non-muscle  myosin  II  (NMHC  II)  is  an  ubiquitously  ex-
pressed  protein  present  in  all  vertebrate  cells.  There  are  three 
known isoforms of NMHC II, namely NMHC II-A, II-B and II-C, 
that have a central role in cell adhesion and differentiation. NMHC 
II-A and B have been demonstrated to be present in human skeletal 
muscle and to localize to Z-lines. NMHC II-C mRNA and pro-
tein has been found widespread in human and mouse organs but 
its localization and function in human skeletal muscle have not 
been investigated. We performed single-labeling immunofluores-
cence, which showed that NMHC II-C is abundantly expressed in 
human skeletal muscle, with a transverse banding pattern of distri-
bution. By double-labeling immunofluorescence with either slow 
myosin heavy chain, desmin, α-actin or α-actinin, we localized 
NMHC II-C overlying the Z-lines and in perinuclear regions. The 
abundance of this protein in association with Z-lines suggests that 
NMHC II-C might play a role in regulating muscle contractility 
or in maintaining integrity of the myofibrillar machinery. Further 
studies need to be performed to establish the exact role of NMHC 
II-C in normal and diseased skeletal muscle.
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Multiple Acyl CoA Dehydrogenase Deficiency (MADD), also 
known as glutaric aciduria type II, is an autosomal recessively inher-
ited disorder of fatty acid metabolism which affects all the fatty-acid 
acyl-CoA dehydrogenase enzyme system. The disorder is usually 
due to defects in the genes of either alpha- or beta-subunit of electron 
transfer flavoprotein (ETFA; MIM# 231680, ETFB; MIM# 130410) 
or ETF dehydrogenase (ETFDH; MIM#231675).
Molecular defects in the ETFDH gene were found to be 
responsible for a specific sub-group of patients affected with 
a variant of the disease responsive to riboflavin (vitamin B2), 
a  precursor  of  flavin  adenine  dinucleotide  (FAD)  and  flavin 
mononucleotide (FMN) required in biological oxidation-reduc-
tion reactions. These patients are usually young adult presenting 
with proximal muscle weakness, exercise intolerance, elevated 
serum CK, cyclical vomiting and episodes of acute encepha-
lopathy, generally precipitated by an infection.
Herein, we report on a patient suffering from a riboflavin-
responsive MADD with no evidence of molecular defects in the 
ETFA, ETFB and ETFDH genes.
The patient was treated with riboflavin at the dosage of 100 
mg/day associated with a low-fatty acid diet. After six months, clin-
ical examination showed global improvement in motor functions.
Our  report  remarks  that  not  all  the  cases  of  riboflavin-
responsive MADD are due to ETFDH mutations, suggesting a 
genetic heterogeneity in this disease. As flavin binding is essen-
tial for the normal function of the Acyl CoA dehydrogenases, 
this riboflavin-responsive disease could be caused by some yet 
unidentified disorder of mitochondrial flavin metabolism and 
transport or flavoprotein homeostasis.
Anyway, in these cases, treatment with riboflavin can be 
alike effective. Therefore, early diagnosis is important to achieve 
the best treatment response.